everybody, Slide Thank on fiscal talk then going through briefly you, just going Abby. Good what run to start we're presentation. call. we'll and thank March for and XX year the to for with I'm a our X about, joining you go morning,
some who noninfectious in in bit well updates about And fixed our then ongoing spend little in review plans a filed months a about Immunovant we brepocitinib of and and We'll give the a earnings actually, of fiscal the talk VTAMA's we'll debt We'll we'll minute a that financial as So It's of will generated where the the of we the that at upcoming X what aren't some the to for uveitis We'll doing little been and catalysts for yesterday or already, as obligations call. spend today update, quarter. a a even VTAMA talk the renegotiation conference on are going significant we'll balance.
We're Q&A. their everybody. that Thank on also of take only who on you, couple data time cost are some out program. us during year. year exciting of a an go bit though amount to burn launch. some we're
we're X I'll XXXX to start balance updates talk be about So exciting the that on and to planning expansion coming just for through always that year updates planned us. includes the and a sarcoidosis the well as data example, fiscal view from generated of that, say, of bunch to Slide and pipeline, our of clinical future already in and out in you're was this a later we some growth And today where of others. and data we'll coming to rest this important continue have as year advance for we year including, that going the of coming brepocitinib data to
our attractive think we couple last stock you'll of capital buyback to communicate make from with price. in finalize to with already of plans Dermavant of we've at atopic now to is We to date year, made to continued shareholders. VTAMA's this major about the SMDA later continue just do psoriasis know, -- to progress and to we finally, communicate end the was Sumitomo, on within months, up the our updates about in a we'll which to program a to repurchased progress return and forward to more late-stage the continuing business to there, talk active are market. very about provide yet thing try, on year development we've And And [ $X.X I that announced as we this And that intend some then for PDUFA this we grow we're at we're year. haven't that that an program ]and plans where and one in activities what in-licensed dermatitis think including looking
I'll the am dermatitis Obviously, specific VTAMA's So us. The in the is get generate the into that say will going about just franchise we better I shaping I have year what we have later important than I never and to TFCM for felt way today underscores atopic before incredibly if that on The this that it pipeline continue grades be do clinical launch have. excited we're in to X, event up. Slide that programs, right an that about we now. we share Immunovant, including franchise data data the
our and in II it noninfectious -- a meeting very minute, and a landscape MVT-XXXX at readouts best got that, year, in franchise in Immunovant, in dual later what this least of talk we've a about dermatomyositis, a really set development which mentioned. competitive more important brepocitinib, And feel As great then program uveitis. JAKX, future this our in program really establishes as our of including has does the sarcoidosis I'll immune. build to data obviously an open that sets I FDA Phase strong we study we've data, in this plan undisclosed and really, ongoing with inhibitor An expect forth had exciting recent to other have the enilumab we've relative And which a that and and then now data some coming, at in type weeks lead clinical that for on in and We just seen all demonstrated position TYKX plans some of really top data of pretty days, the just months. we're program on ever uniqueness our in like pivotal there.
Immunovant going first to Slide on go X. on into updates I'm So
think earnings highlights the portfolio release put I So and Immunovant progress lot I yesterday really there's hit what want are Slide Immunovant the a the on highlighted. out of some key with here that of X. to in just
and most to perhaps all, of First exciting me.
comfortable And And lot do more in because XXXX. fiscal that, to year. of optionality saying really method message many we we With development feel of us, full we supportive. for important the a program think XXXX retain those plan, XXXX to the that studies lot Phase of pivotal around But before over in matter of IP It I track II to development pattern a a XXXX of fact so batoclimab relatively better then on are potentially X serve a this fully is, are a antibody, and point where of We that X to if cases that's going us anti-FcRn finally, out efforts with is user an in way future being behind have composition program optimized extension. can covered recently, we've use of been ton Immunovant. of the we're registration we with to the gives about any that FDA B that notably, to XXXX, as with is Type a inform registrational programs our underappreciated think, we really on development successful think on what patent to that at and held matter, can robust notably issued studies lead data June inform a a meeting for and to topics designed, target manufacturing deliver initiate think to XXXX potentially is best-in-class with patients now is we we clinic. antibody which XXXX value.
Batoclimab
very antibody clinical have really a really of underway obviously that a So time exciting long going with program, target lead here we with our in in lot that development to matter designating a broadly is a promising immunology.
importantly on over looks the like X. been Slide that think positive what So in coming program-specific are overall, years. and Immunovant establishing I some with in upcoming results announcing updates plan. batoclimab is an Immunovant There most overview This One are or updates months that perspective, development from disclose study to together perhaps from Graves planning in we're fall, disease. my now we're detailed
to of reasons, is line frame. know, And with this on share data you expecting and data Immunovant but [indiscernible] we've detail up can begin far believe it, expected lot clarity same ready Top time have year. think fiscal in set for we to As a and expect about also be. we to for MG in seen notably, development it of and and the data fall, what registrational will thus MG share XXXX due to be some Graves are excited we that that competitive this to declined is
we retain a is an about by treat full XXXX plans with indication is quarters unblinding X CIDP. more period This really the for bato X the robust XXXX bato enough study potentially pivotal [indiscernible] that II So to has important optimize the X to of registrational again, CIDP period flexibility And that as think the we in we to is deserves and the Phase prior of for that sort the half enough efficacy. get trying important to to MG extend in as information much decided it will run an in effectively program MG. is patients time are by think population. to developed be data. to about opportunity clear and of where relatively And dose make intent we deeper first enroll and produce that as track that can of and continue next to really study informed on into better sure finally, it's response. indication the understand and severe to we the data in most produce suppression registrational potential that profile the that will we patient another particular, IgG year, be in first-in-class XXXX That's a
different underscore again on deeper our patient data we'll this IgG MG, Slide that very mind slide, been with been but This come we true been a generated own across antibody it's has It's in in that RA reduction data. it degree programs that argenx to response but disease. It's in framing it's with a in in J&J's with generate correlated better Graves' data true and greater is keep to disease That significant new our stated, at year. to competitor the is true shown IgG at And auto point a anti-FcRn and XX. point, want ITP, -- thyroid is I in have show true been true that we greater across it important across has J&J. really patients data. greater to suppression indications and level in clinical that I have the We eye data generated it's reduction UCB and fall antibodies not think different this that matters, consistently a been as
fall better imagination opportunity that's also XXXX year, significant over that think we've clinical high other far But year, the IgG So the to cohort are results I than at supporting want is for we meaningfully in this of as point we're benefit we that And very last response product. is meaningfully indication, Graves approved over But with a fiscal we tapering to on then responses, real XXX this deeper suppression, that a in discontinuation data can drug. the get that so the remind MG there of yet a more points an higher from not ongoing unmet any to think XX we is us space more compared I any say of than where clinical that But further trial sort possible the that with XX-week white lot demonstrate deliver with MG particular, a suggest target best-in-class obviously, better said little efficacy. XXX that is about to proof drugs. supportive both in among want that we in need. that It's also patients saw as thyroid's our patients patients yield What it's to because rates excited generating evidence the exceeded there's for closer set underscore and numerically requires could disease. and matters.
And is everybody, of sort is we dose data we is hypothesis. and again to our patients Slide initial important bit
to expect plans to along class. saw seen produce or in we for and -- people mean look to frankly, the fall IgG this future And And then anything a from, we like competitor to I or important in Graves better what for said, any of best-in-class reduction outside finally, as that with detailed the as picture also where give greater the so as development are we've to of going with the than as demonstrate continue what indication good that's we data XX% meaningfully our at a And program. an inside underscore we dose. XX-milligram
team earlier It's Immunovant to date. call the proud we is we'll some other I'm So I'm sure Priovant And frankly, larger our this that market go of the there uveitis elements appreciate. to on it's on will questions of the think over most we're to. because opportunity be going move an spring a data on exciting. that minutes presented back take now. few to data think people in than pipeline brepocitinib I'm come we've noninfectious a to or recapitulate to in really the we generated going really
uveitis indication, approved of age So our industry. of obviously, are fourth leading disease to an updated with is growth well approved we've widely however, It rapid claims off-label continue includes severe it's the of analysis see the those therapies. this Which in with adalimumab, There significant in as continued non-interior is is a XX,XXX biologics. which number about a the is, working scripts. both There's NIU define therapies. and not -- that a discussed on lot a therapy to we among not only patients difficult blindness morbidities. cause population And as
about talk work in a those therapies biologics a excited that we're already population. that well. the about do not existing That's against So second, we'll backdrop particularly
seen competitors II. And in meaningfully notably, Phase II, data uveitis what better. only with competitors currently III there no far, in number so And we've our of Phase in in Phase limited a are looks
opportunity we point non-interior refractory Slide data differentiated orphan is potential with of a of So with kind broader even opportunities population.
This kind this multibillion-dollar additional peak XX. is biologic our any in post think a population in price on a at sales
I an subpopulation. -- bit I was imagination earlier, treatment. prevalence the at or is the fully But is where overall relevant a required, the population. first we HS think feel is something understanding and people NIU Ted again, so of few as interestingly, like said for But years the of like ago, the if see don't you little there's this the look a the even prevalence in disease, our where
morbidity TNF the like number inflammation including disease. the about about level approved of and think you of disease the this competitors the of a just HS, size us. or against but something reminder, something patients attention high get as competitive other good and treatment you it's sort tolerance [indiscernible] is whether of another want have including is for or same of a the need ocular where the And of no doctors the If an severe things options. ocular that indication think is This market diseases, and like as Ted level also really like opportunity to
It's One work of on who of the the on the HUMIRA was and Slide these call. tapered these And talked which taper. tolerance about if note all aggressive the point that so to a the we've Phase order on used or put dose both II which steroid the a after quickly. preserve So our study Slide high prednisone, we is we would XX, test and rate, non are or thing the drug II basis studies dose-ranging has The mass of that And Phase game double more even patients like. had to called quite studies a the disease endpoint for is benefit name hardest HUMIRA what in show little understand on improvement which on aggressive the then now out improve milligrams. that sort to way a taper, up that burst worsening a approved. able with we be is in put of steroid which failure have here give than is we we XX therapy. goal Meaningfully and our on randomized effectively that of here disease effectively study, was background because is so inflammation, while there sounds completed ocular patients prior treatment what studied milligrams and XX it XX
HUMIRA Slide I enjoy you on the is it's our really This can So XX, the before, a at. failure treatment data. out data we've a really really, XX% own but left we see slide know dose, good side put At discontinuations I high this by looking had on that the XX% had measure rate. our a failure which includes treatment treatment about failure calculation. a treatment on rate. here,
result. and low as twice really a effectively So exciting
On treatment the their treatment failures. They can right-hand HUMIRA discontinuation data side, exclusive it the presents as label. and are they see you in rates
data placebo-controlled about this a point failure the Slide sub-XX% rate both on on and to treatment there, the other So a response had XX% failure on have a endpoints some and study.
One nice dose they should this treatment rate subcomponent XX. of us we on gives sort translatable a confidence that that be last data
HUMIRA put of that these think a developed macular about after edema half macular months, that XX-milligram them about have which X edema HUMIRA, had after by our HUMIRA, it of edema. edema. macular such whereas I about And X baseline. those way, our XX, XX. patients who of about resolution are after patients Maybe XX% XX macular in half there's in and how We think edema, about half patients the patients a had none have macular develop of of XX page, macular like with mutations placebo question who months, didn't week to months, week of patients And this. in came X had was in then And resolution. edema arm by of another and
and opinion about uniqueness another of we data So the Yes. of our opportunity in thinking this that way data underscores again, just have. the set our
opportunity. agents, in early to an prevent think a is And our ability treatment supports I or That this I a as over product thing in the docs, real so no to aggressively as XX, the The opinion, think with basically inflammation option. you'll if intervene This has these brepocitinib differentiated reduce physicians tolerance there's Slide profile reiterate, is far. over inflammation look you ocular call again large to on And just commercial a for to well be agent. shown X. mitigate no really nonsteroidal and certainly is find has blindness. to
continue excited and comes So paring talk and about we together. begin we'll we'll program share about opportunity. as to timeline it, we're more pivotal sign incredibly a it are that and about later this to this for year,
revenue, So the for net going now results about million net VTAMA. I'm yield XX% to to Slide kept to about $XX gross On year for the product the in fiscal transition quarter. which of XX, a
of on. We to continue we a closer end get that psoriasis. grow time improve like goes to about rapid launch talk we guidance notably, time. to sort quite the and Most expect We'll this a have those for steady as numbers as we're dermatitis. of progress over And more in we feel expecting strong atopic foundation in year,
engaged drive and First to standard have AD, on adopter with XX% ability the just a proven we of of care already VTAMA mechanisms slide providers psoriasis XX early early writes the our switches patterns ones all, health in care launch. on the in in from been of psoriasis based novel existing have who
So frankly against in on begin more faster side, a market we this is with. lot topical growing than the to right-hand the is topical many a know with scripts in docs. these AD market backdrop the that psoriasis And of
this exciting So of as as dermatitis. we market spend the set, a data a meaningfully royalty during and we the portion And of that actually than important in people's burn of of our And of up high atopic about came and early minds built one sort for of think lot time think won't on the program some PDUFA sort launch Dermavant year. before, meaningful psoriasis in possible is relatively then reminder, represented debt as launch AD the we've on today early fourth I talked that the update commercial prelaunch market is we've our the acquisition date from us that an infrastructure dynamics Dermavant a we well period. this obligations not are suspect had Again, set different our is on quarter dynamics. which
Dermavant in meaningful deploy I'll our longevity next million, And number on gets to those is the over obligations overall expected X potential renegotiation of X capital we that expect payments to saw burn reduction that our possible. our other which includes $XXX and buying in years $XXX valuable the the our fiscal has theme pretty that a ability counterparties NovaQuest the We about on of reduced focused and successfully million, at it maximizing renegotiated to this by lenders. have to with realize the or of by of a the programs own either minute, about maximum which up are that on investing stock extent hit in we a
we this And as dogmatically so really on rich be where possibly capital cash renegotiation in period is of we focused certainly can as that efficient part we're being and a around this are commitment.
at XX. we important filing Slide repricitinib. this pretty So have some And for we're through the data exciting the point, from coming VTAMA. on through catalysts We're sNDA
data INBormetoclanab from [ and We our have of plans the upcoming development fall. XXXX ] an Graves this overview
study We fourth upcoming Phase in then by in that data have as of Phase trial line data from for [indiscernible] at to IIb studies from And from quarter. back this potentially we the top Immunovant fiscal recent expects line well the to X of namilunab on X our potentially initiate year, FDA XXXX data registrational top II in of as end have interactions. the the positive mistingravis and the CIDP X period
share. $X.X share of our repurchase price billion XX, at on a a program, announced stake this quarter a of reminder, the including this $X.XX repurchase as also, We VTAMA entire
about We continue to we have outstanding. program and that that be commitment, excited
this on time to I'll priced spend I capital. our be be back we expecting say, just shares our with continuing around in And use we We have to it a really of be discovery. buy have of of do may at will protein-protein a probably thoughtful in clear XX, We of efficient coming advantage frankly, really world capability thing. drug take a And prices. attractively best the historically, to way to Slide early-stage there to attractive of is the this, at for a have most. for to where and lot we that work are, visit but it's exciting expect months not the in notably, I that ongoing lot tools the on stock best it the to set not we think some opportunity, expect and spent this moment.
On the I interactions. modeling think think this continue we at In the predicting time out case,
been through discovery AI. and and recently efforts into ] that continue external to with we've true for investment, partnerships recently portion developing Blueprint AI, required our capital to external funding [ mostly capabilities of that and to partnership a both Squibb continues with our progress significant are be Vant entered Vant important have We Bristol-Myers where and are providing the
get business to now. is disputes most court boundaries Finally, date Moderna. we of trial rest the a in the field with against judgment of year expecting motions XX. less a of terms and Page patent in we favorable agreed proposed playing with this as We're and midst time, are through is One the as the sets up clear of for we from X discovery. back other set updates a late on over that questions our of of ligation us the this In of which of year many know, about our year, something summary rest which the you ruling, lot our through in expert distributed a with year, of April the constructions Markman did free than a trial filing Moderna the
our little about study read paid pulmonary people quarter, as historically. cercoidosis. which have that II not as fully has SKU and if orphan untapped that fourth closer the disease potentially registrational ] Cinven that talk say, [ announced attention first a finally, then it it large that to I But we generate in lot We'll therapy is data. especially And out for sarcoidosis, [indiscernible] publicly needless of a X another novel we've would expecting gets of be more it potentially at and markets. that. a opportunity successful, We're point for enrolled that a these to to this Phase to high is forward is looking most that think So
quarter is interest on for million, of is wrap was a we update. a through of So couple here which net won't here. the I finally, Slide our $XXX up that meaningful on cash I'll fact a One utilization I'll all and our including out with things the burn number numbers go point XX. of of a the financial streamlined generate cash things, balance. function that
about XX-K And not as commitment $X.X it's, our quarter was point excited this we again, that. prior debt most on our in ended carrying and again, the capital We part on with a to cash valuable our Sumitomo I'll the value of significant here the efficient that reflect in being out So repurchase opportunities. of to focus deploying we're renegotiation with [indiscernible]. billion this does yet the the with
reflected see you on for So our X/XX renegotiation that will XX-Q the financials.
just it this cases, pipeline excited opportunities and a everything about So we've catalyst with there's of interesting some data XX pipeline a bunch and that, in to I'll to talked addition to as of coming. talk as about for leave off an on on perspective, in our Slide and basis growth just in ongoing bunch say happens. is addition we for And all that soon
So terms over I you, this in joining call, I the up it and I've tuned. that that the of back forward in for about this and I to will excited to space prepared operator your remarks portion questions. what we access.
With look Q&A. morning, for the will hand everybody, that, may wrap of we that either opportunity felt never really about stay set. And be of see opportunities able We're to better Thank
